North America Sickle Cell Disease Market, by Disease Type (Sickle Cell Anemia, Sickle Beta Thalassemia, and Sickle Hemoglobin C Disease), by Drug Type (Hydroxyurea, L-glutamine, Crizanlizumab, Pain-relievers, Voxelotor, and Others), by Distribution Channe

North America Sickle Cell Disease Market, by Disease Type (Sickle Cell Anemia, Sickle Beta Thalassemia, and Sickle Hemoglobin C Disease), by Drug Type (Hydroxyurea, L-glutamine, Crizanlizumab, Pain-relievers, Voxelotor, and Others), by Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Country (U.S and Canada) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Sickle cell disease (SCD) is a group of inherited red blood cell disorders, in which the red blood cells of the individuals become sticky and almost ‘C’ or curved in the shape and therefore the disease is known as sickle cell disease. The sickle cell diseases include sickle cell anemia, sickle cell beta- thalassemia, sickle Hemoglobin C Disease, and others. The various symptoms associated with the sickle cell diseases include anemia, episodes of pain, swelling of hands and feet, and others. Major side effects of hydroxyurea on the long-term treatment in patients suffering from sickle cell disease are gastrointestinal effects such as gastric distress, gastritis, mucositis, and oral mucosa ulcer, dermatological effects such as painful skin ulcers, aphthous ulcers, non-ulcerative toxicity with erythema, and skin infiltration, it can also decrease sperm count and sperm motility in males and can even cause severe interstitial pneumonia. The treatment of the sickle cell disease includes medications and blood transfusions. In some cases of the children and teenagers, a stem cell transplant might also cure the disease.
Market Dynamics
The increasing product approvals by key players for the treatment of sickle cell disease is expected to drive the growth of the North America sickle cell disease market over the forecast period. For instance, in May 2021, Chiesi Farmaceutici S.p.A., a pharmaceutical company, announced that the company had received the U.S. Food Drug and Administration approval for FERRIPROX (deferiprone) indicated for the treatment of transfusional iron overload due to sickle cell disease (SCD) and anemia in pediatric patients of three years old or older and adults.
Key features of the study:
This report provides in-depth analysis of the North America sickle cell disease market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the North America sickle cell disease market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
Key companies covered as a part of this study include Novartis International AG, Bristol-Myers Squibb Company, Bluebird Bio, Global Blood Therapeutics, Inc., Pfizer Inc., Emmaus Life Sciences, Inc., ADDMEDICA, Sangamo Therapeutics, Inc., Acceleron Pharma, Inc., Agios Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals, Inc., and Imara, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The North America sickle cell disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the North America sickle cell disease market
Detailed Segmentation:
North America Sickle Cell Disease Market, By Disease Type:
Sickle Cell Anemia
Sickle Beta Thalassemia
Sickle Hemoglobin C Disease
North America Sickle Cell Disease Market, By Drug Type:
Hydroxyurea
L-glutamine
Crizanlizumab
Pain-relievers
Voxelotor
Others
North America Sickle Cell Disease Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America Sickle Cell Disease Market, By Country:
U.S.
Canada
Company Profiles
Novartis International AG
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Market Strategies
Bristol-Myers Squibb Company
Bluebird Bio
Global Blood Therapeutics, Inc.
Pfizer Inc.
Emmaus Life Sciences, Inc.
ADDMEDICA
Sangamo Therapeutics, Inc.
Acceleron Pharma, Inc.
Agios Pharmaceuticals, Inc.
Chiesi Farmaceutici S.p.A.
Vertex Pharmaceuticals, Inc.
Imara, Inc.
“*” marked represents similar segmentation in other categories in the respective section.